FDA 483 - SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals) - March 15, 2024
FDA 483 for SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals) on March 15, 2024. Product: biologics. Access full analysis and detailed observations.
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
FDA 483 for SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals) on March 15, 2024. Product: biologics. Access full analysis and detailed observations.
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Inspection Date
March 15, 2024
Product Type
biologics
ID: 844c9c7a-b8f2-438a-8fe3-d89cb297cebc
View on DashboardTransform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox